AttayaSuvannasankhaMD

Oncology • Indianapolis, IN

Hematologic Oncology

Assistant Professor, Medicine, Indiana University School of Medicine

Join to view full profile

Dr. Suvannasankha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Suvannasankha's full profile

Already have an account?

Office
980 West Walnut Street, Rm 312
Indianapolis, IN 46202
Phone+1 317-274-0843

Fax+1 317-274-0936
Is this information wrong?

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2000 - 2003
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1997 - 2000
Chulalongkorn University Faculty of MedicineClass of 1996

Certifications & Licensure

IN State Medical License 2003 - 2025
PA State Medical License 1998 - 2000
American Board of Internal Medicine Hematology

Clinical Trials

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma Start of enrollment: 2005 Jun 01
Terminated
Phase 2
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Role of Osteocytes in Myeloma Bone Disease Start of enrollment: 2014 Oct 07
Completed
A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy Start of enrollment: 2021 Dec 06
Withdrawn
Phase 2
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Vic...> ;Cancer. 2024 Apr 17
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar, S., Callander, N., Adekola, K., Anderson, L., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Else...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
1 citations
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 1
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.
Enze Liu, Parvathi Sudha, Nathan Becker, Oumaima Jaouadi, Attaya Suvannasankha, Kelvin Lee, Rafat Abonour, Mohammad Abu Zaid, Brian A Walker> ;Blood Cancer Journal. 2023 Sep 11
2 citations
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma.
Travis S Johnson, Parvathi Sudha, Enze Liu, Patrick Blaney, Gareth Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad ...> ;Research Square. 2023 Aug 16
45 citations
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W C J van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C De Braganc...> ;Blood. 2023 Jan 19
4 citations
GFI1-Dependent Repression ofIncreases Multiple Myeloma Cell Survival.
Daniela N Petrusca, Patrick L Mulcrone, David A Macar, Ryan T Bishop, Evgeny Berdyshev, Attaya Suvannasankha, Judith L Anderson, Quanhong Sun, Philip E Auron, Deborah ...> ;Cancers. 2022 Feb 2
4 citations
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Feng Wang, Cosmina Hogea, Shannon Ferrante, Boris Gorsh, Jenny Willson, Venediktos ...> ;Advances in Therapy. 2021 Sep 24
2 citations
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh, Venediktos Kapetanakis, Jenny Willson, Feng Wang, Cosmina Hogea, Boris Gorsh, Ben Gutierrez, San...> ;Expert Review of Hematology. 2021 Sep 20
82 citations
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Douglas W. Sborov, Attaya Suvannasankha, Ka...> ;Cancer. 2021 Jul 27
438 citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attay...> ;The Lancet. Oncology. 2020 Feb 1
9 citations
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis
Siroj Dejhansathit, Attaya Suvannasankha> ;Journal of Investigative Medicine High Impact Case Reports. 2019 Apr 4
1 citations
Multiple 'doughnut' granulomas in a liver transplant patient with CMV reactivation.
Siroj Dejhansathit, Adam M. Miller, Attaya Suvannasankha> ;BMJ Case Reports. 2018 Nov 1
10 citations
Acute lymphoblastic leukaemia with osteolytic bone lesions: diagnostic dilemma.
Natthapon Angsubhakorn, Attaya Suvannasankha> ;BMJ Case Reports. 2018 Aug 11
3 citations
Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma
Sariya Wongsaengsak, Magdalena Czader, Attaya Suvannasankha> ;BMJ Case Reports. 2018 Jul 10
32 citations
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Konstantinos Lontos, Juraj Adamik, Anastasia Tsagianni, Deborah L. Galson, John M. Chirgwin, Attaya Suvannasankha> ;Frontiers in Endocrinology. 2018 Jun 19
2 citations
Testicular plasmacytoma misdiagnosed as orchitis.
Christopher Schiavo, Steven A. Mann, Jesse Mer, Attaya Suvannasankha> ;BMJ Case Reports. 2018 Jun 4
4 citations
Multifocal myeloid sarcomas: a rare presentation of AML
Natthapon Angsubhakorn, Attaya Suvannasankha> ;BMJ Case Reports. 2017 Oct 4
354 citations
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentz...> ;Blood. 2017 Aug 24
21 citations
Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
Linlin Xu, Khalid S. Mohammad, Hao Wu, Colin D. Crean, Bradley Poteat, Yinghua Cheng, Angelo A. Cardoso, Christophe Machal, Helmut Hanenberg, Rafat Abonour, Melissa A....> ;Cancer Research. 2016 Dec 1
Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss
Mark A. Gromski, Jennifer L. Peng, Jiehao Zhou, Howard C. Masuoka, Attaya Suvannasankha, Suthat Liangpunsakul> ;Journal of Investigative Medicine High Impact Case Reports. 2016 Dec 1
3 citations
Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
Hamid Sayar, Yan Liu, Rui Gao, Mohammad Abu Zaid, Larry D. Cripe, Jill Weisenbach, Katie J. Sargent, Mehdi Nassiri, Lang Li, Heiko Konig, Attaya Suvannasankha, Feng Pa...> ;Oncotarget. 2015 Nov 7
8 citations
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Joshua A. Waters, Jesus M. Matos, Michele T. Yip-Schneider, Juan R. Aguilar-Saavedra, Colin D. Crean, Joal D. Beane, Ryan P. Dumas, Attaya Suvannasankha, C. Max Schmidt> ;Surgery. 2015 Oct 1
36 citations
FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
Attaya Suvannasankha, Douglas R. Tompkins, Daniel F. Edwards, Katarina V. Petyaykina, Colin D. Crean, Pierrick G.J. Fournier, Jamie M. Parker, George E. Sandusky, Shoj...> ;Oncotarget. 2015 Apr 12
Join now to see all

Press Mentions

First-in-Human Multiple Myeloma Study Shows 90 Percent Response RateApril 19th, 2023
Early Data Indicates New Therapy Is ‘Safe and Effective’ for Cancer Metastases in BonesApril 29th, 2021
Purdue Researchers at Work on Anemia App to Make Detection EasierNovember 30th, 2017